CMS introduced in a press release that it has proposed to cover acupuncture as a possible alternative remedy to opioid use for Medicare beneficiaries with chronic low returned pain who are enrolled in medical trials sponsored through the NIH or in CMS-permitted trials.
“Today’s inspiration represents the Trump administration’s commitment to imparting Americans with access to a wide range of options to support their fitness,” Alex M. Azar II, HHS Secretary, said in the release. “Defeating our United States’ epidemic of opioid addiction requires identifying all viable approaches to deal with the very actual hassle of persistent pain, and this idea would provide patients with new options while increasing our scientific information on opportunity methods to pain.”
According to the release, CMS has collaborated with the NIH as part of the Opioids Workgroup and Evidence Generation Workgroup to start research on acupuncture to remedy chronic low again pain in sufferers aged 65 years or older. With the proposed decision, CMS and NIH will continue to broaden evidence for Medicare insurance determinations for acupuncture treatment for beneficiaries with chronic low back pain.
“Chronic lower back ache influences many Medicare patients and is a main purpose for opioid prescribing,” CMS Principal Deputy Administrator of Operations and Policy Kimberly Brandt said in the release. “ … CMS will work intently with our sister businesses to reveal results for Medicare beneficiaries receiving acupuncture to inform our knowledge of the efficacy of this healing technique.
On July 15, 2019, CMS announced its purpose to allow acupuncture for sufferers with persistent low returned pain to be a covered service provided they have been enrolled in a clinical trial that changed into evaluating the efficacy of acupuncture and measuring scientific outcomes. This exchange comes as part of a broad effort to discover various pain management options to provide alternatives to opioid pain medicines. Acupuncture is founded based totally on scientific ideas of
body structure and has been proven to be powerful for many clinical situations. It is uncertain whether it will prove to be an efficacious modality to manage persistent low backache, but this represents a prime step in facilitating clinical trials that might solve that question. The truth that CMS has restrained insurance first of all to sufferers enrolled in clinical trials will make certain that records evaluating the efficacy of this technique are acquired earlier than a huge coverage decision is made, and this represents a apt method of spending our restrained pool of CMS greenbacks on treatments with verified efficacy.
